June 10, 2026

Camurus Oclaiz PDUFA Day, Wegovy Pill 3M Scripts in 5 Months, Lantheus PNT2003 30-Month Stay Expires, Peptide Industry Federal Enforcement Watch

PDUFA day for Camurus Oclaiz octreotide depot, Wegovy pill hits 3M US scripts in 5 months, Lantheus PNT2003 stay expires, and the peptide-enforcement watch.

7 stories · Covering regulatory, industry

Editor's Note

Two non-obesity peptide stories anchored the day. Camurus reached the FDA's PDUFA target action date of June 10 for Oclaiz, the monthly octreotide depot for acromegaly that would become the second once-monthly subcutaneous option in a category long defined by intramuscular dosing. Lantheus's Lutathera radioequivalent PNT2003 has the 30-month Hatch-Waxman stay expiring this month, the next gate to a US launch in neuroendocrine tumors. On the obesity side, Novo Nordisk's Wegovy pill 3-million-script milestone in five months puts a hard number on the oral-incretin demand curve the field has been arguing about since January. Off the data axis, AMC Defense Law's note on incoming federal peptide-industry charges plus the FDA's compounding tightening keeps the enforcement thread alive ahead of the July 23-24 PCAC meeting.

Regulatory

Camurus Oclaiz (Octreotide Depot) PDUFA Action Date Today: Decision Awaited on Monthly Acromegaly Therapy

Camurus's resubmitted NDA for Oclaiz (CAM2029), a monthly subcutaneous octreotide depot built on the company's FluidCrystal technology and delivered by autoinjector pen, carries an FDA PDUFA target action date of June 10. The resubmission, accepted in January 2026 after a Complete Response Letter tied solely to a third-party manufacturing inspection, rests on data from seven clinical studies including the two Phase 3 ACROINNOVA trials. A clearance would put Oclaiz alongside Crinetics' Palsonify (paltusotine) as the second new-mechanism acromegaly therapy in the past year, with the Camurus FluidCrystal differentiation focused on a small-volume monthly self-injection.

#camurus #oclaiz #octreotide #acromegaly #somatostatin #pdufa #fluidcrystal

Industry

Novo Nordisk Wegovy Pill Surpasses 3 Million US Prescriptions in 5 Months Since January 5 Launch, 80% to GLP-1-Naive Patients

A June 7 Novo Nordisk announcement, timed to ADA 2026, said the Wegovy pill (oral semaglutide 25 mg) had surpassed 3 million US prescriptions since its January 5 launch, with one prescription filled roughly every five seconds. The first million took 12 weeks (to March 23); the next 2 million came in 10 weeks. More than 80% of new Wegovy pill scripts go to patients new to GLP-1 therapy, suggesting market expansion rather than brand switching, and the first international launches outside the US are set for the second half of 2026.

#novo-nordisk #wegovy-pill #oral-semaglutide #prescription-tracker #international-launch

Regulatory

Lantheus PNT2003 Lutathera Radioequivalent: 30-Month Hatch-Waxman Stay Expires June 2026, Final FDA Approval Within Reach

Lantheus's lutetium-177 dotatate ANDA (PNT2003), the first radioequivalent to Novartis's Lutathera, received FDA tentative approval on March 2, 2026; full approval is gated by the expiration of the 30-month Hatch-Waxman stay in June 2026. PNT2003 would launch into the gastroenteropancreatic neuroendocrine-tumor (GEP-NET) market alongside Lutathera and ahead of ITM-11 (Lu-edotreotide-177), which carries an August 28 PDUFA. Lantheus licensed PNT2003 from POINT Biopharma in December 2022, before Lilly's POINT acquisition.

#lantheus #pnt2003 #lutathera #lutetium-177 #neuroendocrine-tumors #radioligand #hatch-waxman

Regulatory

Peptide Industry Federal Enforcement Watch: AMC Defense Law Flags Coming Charges Against Compounders, Telehealth, and Vendors

AMC Defense Law's June 2026 'Justice Watch' note read the peptide enforcement signal: compounding pharmacies receiving warning letters and losing licenses, telehealth companies facing criminal indictments, and bulk-substance vendors under federal scrutiny. The FDA has issued more than 50 warning letters to peptide vendors and compounders in 2024-2025, and the agency has signaled an aggressive 503A/503B stance heading into the July 23-24 PCAC meeting that will rule on whether seven peptides return to legal compounding status.

#fda-enforcement #503a-compounding #telehealth #pcac #criminal-charges #warning-letters

Industry

Hims & Hers Annual Meeting June 11: $2.35B 2025 Revenue, 2.5M+ Subscribers, GLP-1 Pivot to Lilly Foundayo and Novo Wegovy

Hims & Hers' proxy report ahead of the June 11 virtual annual meeting shows 2025 revenue at $2.35 billion (up 59%), 2.5 million-plus subscribers, $318 million adjusted EBITDA, and $300 million operating cash flow. The company's GLP-1 pivot now leans on the Lilly tie-up (Zepbound vials and KwikPens, plus Foundayo via LillyDirect; Bank of America lifted its price target to $32) and the renewed Novo Nordisk partnership for branded Wegovy. The compounded-semaglutide business is winding down ahead of the FDA 503B exclusion that becomes effective after the June 29 comment window closes.

#hims-and-hers #telehealth #foundayo #wegovy #annual-meeting #lillydirect

Industry

Berobenatide and the Monthly Dosing Question: Pfizer's $4.9B Metsera Acquisition Pays Out at ADA 2026

Pfizer's ADA Phase 2b readout for berobenatide (15.9% weight loss at 32 weeks, no plateau, monthly dosing via a 0.5 mL low-volume injection) validates the $4.9 billion Metsera acquisition that closed earlier this year. The company now plans more than 20 obesity-related trials in 2026, including 10 Phase 3 studies. Monthly dosing positions berobenatide against once-weekly incumbents on the adherence axis, the same logic behind Amgen's MariTide and Ascletis's ASC30.

#pfizer #berobenatide #metsera #monthly-glp-1 #acquisition #ada-2026

Regulatory

503B GLP-1 Compounding Comment Window Closes June 29: Industry Watch as FDA Finalizes Exclusion of Semaglutide, Tirzepatide, Liraglutide

The FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list approaches its June 29 comment-window close. Once finalized, the rule effectively bars large-scale compounding of these GLP-1s under any clinical-need exception, accelerating the wind-down already underway among compounders (ProRx, BPI Labs, the Hims-affiliated manufacturer Medisource). Compounded GLP-1 telehealth platforms have largely pivoted to branded-drug fulfillment or microdose protocols, with the regulatory cliff at three weeks out.

#fda #503b-compounding #semaglutide #tirzepatide #liraglutide #comment-period